Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial

0TipInsights

Authors

Glen Kennedy•Antiopi Varelias22 more•Geoffrey Hill

Journal

The Lancet Oncology

Published

November 17, 2014

Supporters

Support the authors with ResearchCoin

Tip RSC

Topics

Physics

Optics

Immunology

Medicine

Internal Medicine

Show all topics

DOI

10.1016/s1470-2045(14)71017-4

License

Unknown License